SOUTH SAN FRANCISCO, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE), today announced that Sharon E. Tetlow, senior
vice president and chief financial officer of Cell Genesys, will present a
company update at the BIO Investor Forum in San Francisco, CA that will be
broadcast live over the internet on Wednesday, October 19, 2005 at 4:40 p.m.
PT.
The webcast will be available on the Investor Relations section of the
Cell Genesys website, http://www.cellgenesys.com. If you are unable to listen to the
live webcast, it will be archived on the site for at least two weeks following
the presentation. To access the replay, go to the Investor Relations section
of the site.
Cell Genesys is focused on the development and commercialization of novel
biological therapies for patients with cancer. The company is currently
pursuing two clinical stage product platforms -- GVAX(R) cancer vaccines and
oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of
GVAX(R) vaccine for prostate cancer, Phase 2 trials of GVAX(R) vaccines for
leukemia and pancreatic cancer, and a Phase 1 trial of CG0070 oncolytic virus
therapy for bladder cancer and potentially other types of cancer. Cell
Genesys continues to hold equity interests in its two former subsidiaries --
Abgenix, Inc., an antibody products company, and Ceregene, Inc., which is
developing gene therapies for neurodegenerative disorders. Cell Genesys is
headquartered in South San Francisco, CA and has its principal manufacturing
operation in Hayward, CA. For additional information, please visit the
company's website at http://www.cellgenesys.com.
Statements made herein about the company, other than statements of
historical fact, including statements about the company's progress, financial
results, timing and results of clinical trials and preclinical programs, and
the nature of product pipelines are forward-looking statements and are subject
to a number of uncertainties that could cause actual results to differ
materially from the statements made, including risks associated with the
success of clinical trials and research and development programs, the
regulatory approval process for clinical trials, competitive technologies and
products, patents, continuation of corporate partnerships and the need for
additional funding. For information about these and other risks which may
affect Cell Genesys, please see the company's Annual Report on Form 10-K for
the year ended December 31, 2004 filed on March 14, 2005 as well as Cell
Genesys' reports on Form 10-Q and 8-K and other reports filed from time to
time with the Securities and Exchange Commission. The company assumes no
obligation to update the forward-looking information in this press release.
Contact: Ina Cu
Investor Relations
650-266-3200
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Ina Cu, Investor Relations of Cell Genesys,
Inc., +1-650-266-3200
|
